Solasonine Causes Redox Imbalance and Mitochondrial Oxidative Stress of Ferroptosis in Lung Adenocarcinoma.
ferroptosis
lung adenocarcinoma
mitochondrial dysfunction
oxidation
solasonine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
02
2022
accepted:
24
03
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Ferroptosis, a type of iron-dependent oxidative cell death caused by excessive lipid peroxidation, is emerging as a promising cancer therapeutic strategy. Solasonine has been reported as a potential compound in tumor suppression, which is closely linked to ferroptosis. However, ferroptosis caused by solasonine is insufficiently identified and elaborated in lung adenocarcinoma, a fatal disease with high morbidity and mortality rates. First, the biochemical and morphological changes in Calu-1 and A549 cells exposed to solasonine are observed using a cell death assay and a microscope. The cell viability assay is performed after determining the executive concentration of solasonine to assess the effects of solasonine on tumor growth in Calu-1 and A549 cells. The ferroptosis is then identified by using ferroptosis-related reagents on CCK-8, lipid peroxidation assessment, Fe
Identifiants
pubmed: 35664792
doi: 10.3389/fonc.2022.874900
pmc: PMC9158126
doi:
Types de publication
Journal Article
Langues
eng
Pagination
874900Informations de copyright
Copyright © 2022 Zeng, Luo, Ju, Zhang, Cui, Pan, Tian, Teng, Wu and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Adv Mater. 2019 Dec;31(51):e1904197
pubmed: 31595562
Cell Res. 2016 Sep;26(9):1021-32
pubmed: 27514700
Front Pharmacol. 2018 Nov 22;9:1371
pubmed: 30524291
Cell Death Differ. 2016 Mar;23(3):369-79
pubmed: 26794443
Bioorg Med Chem Lett. 2010 Jul 1;20(13):3911-5
pubmed: 20605449
Eur J Cell Biol. 2020 Jan;99(1):151058
pubmed: 31810634
J Clin Invest. 2021 Nov 15;131(22):
pubmed: 34609966
Cancer Sci. 2018 Sep;109(9):2757-2766
pubmed: 29917289
Free Radic Biol Med. 2002 Aug 15;33(4):473-90
pubmed: 12160930
Cell Res. 2019 May;29(5):347-364
pubmed: 30948788
J Hematol Oncol. 2019 Mar 29;12(1):34
pubmed: 30925886
Nat Commun. 2020 Jan 3;11(1):102
pubmed: 31900386
Fundam Clin Pharmacol. 2019 Aug;33(4):385-396
pubmed: 30628118
Am J Cancer Res. 2020 Oct 01;10(10):3106-3126
pubmed: 33163260
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
Cancer Res Treat. 2018 Apr;50(2):445-460
pubmed: 28494534
Chem Biol. 2008 Mar;15(3):234-45
pubmed: 18355723
Nat Cell Biol. 2014 Dec;16(12):1180-91
pubmed: 25402683
Biomark Res. 2021 Nov 6;9(1):82
pubmed: 34742351
Nat Rev Clin Oncol. 2021 May;18(5):280-296
pubmed: 33514910
Front Oncol. 2021 Jan 29;10:614067
pubmed: 33585239
Cell Death Dis. 2018 Jan 25;9(2):117
pubmed: 29371589
Am J Transl Res. 2020 Jul 15;12(7):3522-3530
pubmed: 32774717
Biomed Pharmacother. 2020 Sep;129:110282
pubmed: 32531676
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
Nat Rev Cancer. 2019 Jul;19(7):405-414
pubmed: 31101865
Zhongguo Fei Ai Za Zhi. 2015 Jul;18(7):416-21
pubmed: 26182866
Mol Cell. 2019 Jan 17;73(2):354-363.e3
pubmed: 30581146
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
Semin Cancer Biol. 2020 Nov;66:89-100
pubmed: 30880243
Am J Transl Res. 2017 Sep 15;9(9):3977-3989
pubmed: 28979674
J Cell Mol Med. 2019 Aug;23(8):4900-4912
pubmed: 31232522
Oncogene. 2018 Sep;37(36):5007-5019
pubmed: 29789716